Mechanism of Action.
MOTS-c is a 16-amino-acid peptide encoded by the mitochondrial genome within the 12S rRNA gene, making it one of several mitochondrial-derived peptides (MDPs) with signaling functions. Its primary mechanism involves activation of the AMPK (AMP-activated protein kinase) pathway, a master metabolic sensor. MOTS-c inhibits the folate-methionine cycle, leading to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which activates AMPK. This triggers downstream effects including enhanced glucose uptake via GLUT4 translocation, increased fatty acid oxidation, improved mitochondrial biogenesis, and suppression of the mTOR pathway. MOTS-c also translocates to the nucleus during metabolic stress, directly regulating gene expression through interactions with ARE (antioxidant response element) and NRF2 pathways.
Research Summary.
The foundational study by Lee et al. (2015) in Cell Metabolism demonstrated that MOTS-c administration prevented diet-induced obesity and insulin resistance in mice. Subsequent research showed that MOTS-c levels decline with age, correlating with metabolic dysfunction. A 2019 study found that circulating MOTS-c levels increase with exercise in humans, suggesting it functions as an exercise-mimetic signal. Research has shown MOTS-c improves glucose homeostasis in aged mice, enhances exercise capacity, and may protect against age-related metabolic decline. Studies also indicate anti-inflammatory properties and potential cardiovascular benefits through endothelial function improvement.
Side Effects & Safety.
MOTS-c is an endogenous peptide that the body naturally produces, which theoretically supports a favorable safety profile. However, as a research compound, there are no completed human clinical trials establishing formal safety data. Preclinical studies have not identified significant adverse effects at physiological doses. Theoretical concerns include potential interactions with other AMPK-modulating compounds and unknown effects of supraphysiological dosing on mitochondrial dynamics and cellular energy balance. The relatively recent discovery of MOTS-c (2015) means long-term research data is limited.
Legal Status & Access.
MOTS-c is classified as a Category 1 research peptide. It is not FDA-approved for any clinical indication and has not yet entered formal clinical trials. It is available from research peptide suppliers for laboratory investigation.